Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (311-320 of 324) with videos related to

Pageof 33
Sort By:
The Lancet. Infectious Diseases|October 13, 2012
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trialThanyawee Puthanakit, Vonthanak Saphonn, Jintanat Ananworanich, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2010
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trialsRoy T Steigbigel, David A Cooper, Hedy Teppler, et al.
Journal of Virus Eradication|June 14, 2019
Possible clearance of transfusion-acquired <i>nef</i>/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Δ32 heterozygous and HLA-B57 genotypeJohn Zaunders, Wayne B Dyer, Melissa Churchill, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 29, 2017
Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected IndividualsKersten K Koelsch, Thomas A Rasmussen, William J Hey-Nguyen, et al.
The New England Journal of Medicine|July 25, 2008
Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel, David A Cooper, Princy N Kumar, et al.
The New England Journal of Medicine|July 25, 2008
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper, Roy T Steigbigel, Jose M Gatell, et al.
Nature Medicine|February 17, 2009
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cellsRonald T Mitsuyasu, Thomas C Merigan, Andrew Carr, et al.
Nature Communications|November 5, 2023
Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skinQi Tang, Hassan H Fakih, Mohammad Zain Ui Abideen, et al.
Pageof 33

Showing results (311-320 of 324) with videos related to

Sort By:
Pageof 33
The Lancet. Infectious Diseases|October 13, 2012
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trialThanyawee Puthanakit, Vonthanak Saphonn, Jintanat Ananworanich, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2010
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trialsRoy T Steigbigel, David A Cooper, Hedy Teppler, et al.
Journal of Virus Eradication|June 14, 2019
Possible clearance of transfusion-acquired <i>nef</i>/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Δ32 heterozygous and HLA-B57 genotypeJohn Zaunders, Wayne B Dyer, Melissa Churchill, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 29, 2017
Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected IndividualsKersten K Koelsch, Thomas A Rasmussen, William J Hey-Nguyen, et al.
The New England Journal of Medicine|July 25, 2008
Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel, David A Cooper, Princy N Kumar, et al.
The New England Journal of Medicine|July 25, 2008
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper, Roy T Steigbigel, Jose M Gatell, et al.
Nature Medicine|February 17, 2009
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cellsRonald T Mitsuyasu, Thomas C Merigan, Andrew Carr, et al.
Nature Communications|November 5, 2023
Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skinQi Tang, Hassan H Fakih, Mohammad Zain Ui Abideen, et al.
Pageof 33